Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials

HIGHLIGHTS

• who: Le-Tian Huang from the Department of Oncology, Shengjing Hospital of China Medical University have published the research work: Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials, in the Journal: (JOURNAL) of March/30,/2020
• what: On the basis of the answers to these three questions, we have made preliminary recommendations for first-line and maintenance treatment strategies for patients with advanced NS-NSCLC . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.